Oncotelic Therapeutics, Inc. has successfully completed the initial safety cohort study of its Phase 1B SP-03-B101 clinical trial.

老虎证券2026/07/07 13:54

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

It is worth noting that an independent safety review committee has reviewed relevant data and officially recommended proceeding to the next phase of dose escalation research. Meanwhile, the company is actively promoting the expansion of this trial in Europe, marking an important advancement in its research and development pipeline.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncotelic Therapeutics, Inc. has successfully completed the initial safety cohort study of its Phase 1B SP-03-B101 clinical trial.

You may also like

Crypto prices